Galapagos (NASDAQ:GLPG) Given Equal Weight Rating at Morgan Stanley

Morgan Stanley restated their equal weight rating on shares of Galapagos (NASDAQ:GLPG) in a research note issued to investors on Monday, Benzinga reports. They currently have a $38.00 price target on the biotechnology company’s stock.

A number of other research analysts also recently issued reports on GLPG. StockNews.com downgraded shares of Galapagos from a buy rating to a hold rating in a research report on Monday, March 18th. Bank of America reissued an underperform rating and set a $31.00 price objective (down from $41.00) on shares of Galapagos in a research report on Thursday, March 28th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and one has issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of Hold and a consensus price target of $34.50.

Galapagos Stock Down 0.0 %

Shares of NASDAQ GLPG opened at $29.07 on Monday. The firm’s fifty day moving average is $33.91 and its 200 day moving average is $36.41. The company has a market cap of $1.92 billion, a price-to-earnings ratio of -12.69 and a beta of 0.25. Galapagos has a 52 week low of $28.82 and a 52 week high of $45.21.

Institutional Trading of Galapagos

Hedge funds and other institutional investors have recently modified their holdings of the business. GAMMA Investing LLC purchased a new stake in shares of Galapagos in the 4th quarter worth about $44,000. Quadrant Capital Group LLC boosted its stake in Galapagos by 18.1% in the 4th quarter. Quadrant Capital Group LLC now owns 1,706 shares of the biotechnology company’s stock worth $69,000 after purchasing an additional 261 shares in the last quarter. Tower Research Capital LLC TRC boosted its stake in Galapagos by 2,317.5% in the 4th quarter. Tower Research Capital LLC TRC now owns 1,934 shares of the biotechnology company’s stock worth $79,000 after purchasing an additional 1,854 shares in the last quarter. Signaturefd LLC boosted its stake in Galapagos by 78.6% in the 4th quarter. Signaturefd LLC now owns 1,970 shares of the biotechnology company’s stock worth $80,000 after purchasing an additional 867 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. boosted its stake in Galapagos by 357.6% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 2,265 shares of the biotechnology company’s stock worth $92,000 after purchasing an additional 1,770 shares in the last quarter. 32.46% of the stock is owned by hedge funds and other institutional investors.

Galapagos Company Profile

Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of?various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and uveitis.